Precision Biosciences (DTIL) Free Cash Flow (2018 - 2026)
Precision Biosciences (DTIL) reported Free Cash Flow of -$12.0 million for Q1 2026, up 37.46% year-over-year from -$8.7 million in Q1 2025, and down 6.09% quarter-over-quarter from -$11.3 million in Q4 2025.
Precision Biosciences (DTIL) Free Cash Flow (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Free Cash Flow data on file, last reported at -$12.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$12.0 million, up 37.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$58.8 million (changed 0.04% YoY), and the FY2025 annual result was -$65.9 million, down 12.32% from the prior year.
- Free Cash Flow eased to -$12.0 million in Q1 2026 per DTIL's latest filing, from -$11.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $28.1 million in Q3 2022 and troughed at -$32.0 million in Q1 2023.
- A 5-year average of -$16.0 million and a median of -$19.1 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 214.04% in 2022, then sank 183.57% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$22.5 million in 2022, then jumped by 62.64% to -$8.4 million in 2023, then plunged by 123.65% to -$18.8 million in 2024, then surged by 39.99% to -$11.3 million in 2025, then dropped by 6.09% to -$12.0 million in 2026.
- Business Quant data shows DTIL's Free Cash Flow at -$12.0 million in Q1 2026, -$11.3 million in Q4 2025, and -$15.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | -11.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.96 Mn |
| Mar 31, 2026 | -11.96 Mn |
| Dec 31, 2025 | -11.27 Mn |
| Dec 31, 2025 | -11.27 Mn |
| Sep 30, 2025 | -15.27 Mn |
| Sep 30, 2025 | -15.27 Mn |
| Jun 30, 2025 | -20.27 Mn |
| Jun 30, 2025 | -20.27 Mn |
| Mar 31, 2025 | -19.12 Mn |
| Mar 31, 2025 | -19.12 Mn |
| Dec 31, 2024 | -18.78 Mn |
| Dec 31, 2024 | -18.78 Mn |
| Sep 30, 2024 | -5.95 Mn |
| Sep 30, 2024 | -5.95 Mn |
| Jun 30, 2024 | -14.90 Mn |
| Jun 30, 2024 | -14.90 Mn |
| Mar 31, 2024 | -19.07 Mn |
| Mar 31, 2024 | -19.07 Mn |
| Dec 31, 2023 | -8.40 Mn |
| Dec 31, 2023 | -8.40 Mn |